Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elutia (ELUT) Non-Current Deffered Revenue (2019 - 2021)

Elutia recorded quarterly Non-Current Deffered Revenue of $936000.0 in Q3 2021, up 7.59% quarter-over-quarter from $870000.0 in Q2 2021, and up 77.61% year-over-year from $527000.0 in Q3 2020.

Elutia's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $936000.0 for Q3 2021.

  • In Q3 2021, Non-Current Deffered Revenue rose 77.61% year-over-year to $936000.0; the TTM figure through Sep 2021 stood at $936000.0 (up 77.61% YoY), while the FY2020 annual figure was $756000.0, up 7.23% from the prior year.
  • Non-Current Deffered Revenue came in at $936000.0 for Q3 2021 at Elutia, up from $870000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $936000.0 in Q3 2021 to a low of $527000.0 in Q3 2020.
  • A 3-year average of $770666.7 and a median of $793000.0 in 2020 frame the typical range for Non-Current Deffered Revenue.
  • Across the five-year window, Non-Current Deffered Revenue gained 7.23% in 2020 and surged 77.61% in 2021, its largest moves.
  • Elutia's Non-Current Deffered Revenue stood at $705000.0 in 2019, then increased by 7.23% to $756000.0 in 2020, then rose by 23.81% to $936000.0 in 2021.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $936000.0, $870000.0, and $830000.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 512.79 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Elutia 45.79 Mn 17.31 Mn 1.80 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 936,000.00
Jun 30, 2021 870,000.00
Mar 31, 2021 830,000.00
Dec 31, 2020 756,000.00
Sep 30, 2020 527,000.00
Dec 31, 2019 705,000.00